Major investment in AI-powered drug discovery
Boltz, a startup developing artificial intelligence models for molecular design and drug discovery, has announced $110 million in Series A funding led by Bessemer Venture Partners.
The investment will support the company’s research, computing infrastructure and expansion as pharmaceutical businesses explore ways to use AI in medicine development.
Existing investors Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures also participated. New investors include Greycroft, F-Prime Capital and Benchling.
How Boltz uses AI
Traditional drug discovery involves extensive laboratory research and repeated experiments. Scientists must identify promising molecules, test their properties and refine candidates through multiple stages.
Boltz is developing AI models intended to help researchers predict molecular behaviour and design potential drug candidates using computational methods.
Its models include BoltzMol-1 for small-molecule discovery and BoltzProt-1 for protein design.
Commercial partnerships
The company says it has signed partnerships with six of the world’s 20 largest pharmaceutical companies. It also reported that molecular token usage among paying customers increased 50-fold since June.
These are company-reported figures, but they indicate growing commercial interest in AI tools for scientific research.
Why investors are interested
Pharmaceutical research is expensive and time-consuming. AI-assisted molecular design could help researchers explore more possibilities and prioritise experiments more efficiently.
However, computational predictions do not replace laboratory validation, clinical trials or regulatory approval. Any potential medicine must still demonstrate safety and effectiveness through established scientific processes.
What happens next
Boltz plans to invest in computing resources, data and hiring to support growing demand. Its progress will depend on whether its models consistently deliver useful results for research partners and become integrated into drug-development workflows.
